Last reviewed · How we verify
Mannitol Inhalant Product
Mannitol Inhalant Product is a Osmotic agent / Airway clearance agent Small molecule drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved for Cystic fibrosis (to improve airway clearance and lung function), Bronchiectasis (to improve airway clearance). Also known as: Bronchitol; dry powder mannitol.
Mannitol inhalant acts as an osmotic agent that draws fluid into the airways to hydrate secretions and promote airway clearance.
Mannitol inhalant acts as an osmotic agent that draws fluid into the airways to hydrate secretions and promote airway clearance. Used for Cystic fibrosis (to improve airway clearance), Bronchiectasis (to improve airway clearance).
At a glance
| Generic name | Mannitol Inhalant Product |
|---|---|
| Also known as | Bronchitol; dry powder mannitol |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Osmotic agent / Airway clearance agent |
| Modality | Small molecule |
| Therapeutic area | Pulmonology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
When inhaled as a dry powder, mannitol particles absorb moisture from the airway epithelium and surrounding tissues, creating an osmotic gradient that increases airway surface liquid volume. This hydration of mucus and improved clearance helps mobilize secretions and may stimulate cough-mediated clearance, improving mucociliary function in patients with compromised airway clearance.
Approved indications
- Cystic fibrosis (to improve airway clearance and lung function)
- Bronchiectasis (to improve airway clearance)
Common side effects
- Cough
- Throat irritation
- Bronchospasm
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mannitol Inhalant Product CI brief — competitive landscape report
- Mannitol Inhalant Product updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI
Frequently asked questions about Mannitol Inhalant Product
What is Mannitol Inhalant Product?
How does Mannitol Inhalant Product work?
What is Mannitol Inhalant Product used for?
Who makes Mannitol Inhalant Product?
Is Mannitol Inhalant Product also known as anything else?
What drug class is Mannitol Inhalant Product in?
What development phase is Mannitol Inhalant Product in?
What are the side effects of Mannitol Inhalant Product?
Related
- Drug class: All Osmotic agent / Airway clearance agent drugs
- Manufacturer: University of North Carolina, Chapel Hill — full pipeline
- Therapeutic area: All drugs in Pulmonology / Respiratory
- Indication: Drugs for Cystic fibrosis (to improve airway clearance and lung function)
- Indication: Drugs for Bronchiectasis (to improve airway clearance)
- Also known as: Bronchitol; dry powder mannitol
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing